CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-03 | Smethurst Dominic Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-01-03 | Skynner Michael Chief Technology Officer | Grant or award | +17,500 | 73,623 | ||
| 2023-01-03 | Skynner Michael Chief Technology Officer | Sale | −1,801 | $29.06 | $52K | 71,822 |
| 2023-01-03 | Skynner Michael Chief Technology Officer | Grant or award · Employee Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award | +17,500 | 40,977 | ||
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Sale | −1,817 | $29.06 | $53K | 39,160 |
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-01-03 | Kalowski Lee President and CFO | Grant or award | +17,500 | 32,500 | ||
| 2023-01-03 | Kalowski Lee President and CFO | Sale | −1,815 | $29.06 | $53K | 30,685 |
| 2023-01-03 | Kalowski Lee President and CFO | Grant or award · Employee Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-01-03 | Bourque Janice Director | Grant or award | +5,750 | 10,750 | ||
| 2023-01-03 | Bourque Janice Director | Grant or award · Stock Option (right to buy) | +11,500 | 11,500 | ||
| 2023-01-03 | Kender Richard N Director | Grant or award | +5,750 | 10,750 | ||
| 2023-01-03 | Kender Richard N Director | Grant or award · Stock Option (right to buy) | +11,500 | 11,500 | ||
| 2023-01-03 | Gutierrez-Ramos Jose-Carlos Director | Grant or award | +5,750 | 10,750 | ||
| 2023-01-03 | Gutierrez-Ramos Jose-Carlos Director | Grant or award · Stock Option (right to buy) | +11,500 | 11,500 | ||
| 2023-01-03 | Lee Kevin Chief Executive Officer | Grant or award | +57,500 | 332,585 | ||
| 2023-01-03 | Lee Kevin Chief Executive Officer | Sale | −6,000 | $29.06 | $174K | 326,585 |
| 2023-01-03 | Lee Kevin Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2023-01-03 | Legault Pierre Director | Grant or award | +11,500 | 21,500 |
Page 16 of 26 · 520 trades